Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...
MedPage Today1d
Year in Review: Early Breast Cancer
News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
Analytics India Magazine1d
AlphaFold 3 is Now Open Source—A New Era in Protein Prediction
In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...
TheHealthSite3d
What Are The Most Effective Treatments For Stage 4 Breast Cancer?
CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...
News Medical5d
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder
Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...
TMCnet6d
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Revenue: Revenue was $0 for the third quarter of 2024, as compared to $25.2 million for the third quarter of 2023. The decrease was primarily due to the recognition of previously received milestone ...